An ophthalmic therapeutic company in the business of commercializing innovative treatments for age-related eye diseases, including age-related macular degeneration, or AMD, and glaucoma.


Updates from The Motley Fool

Latest updates on TearLab from Fool.com.
Why TearLab Corp. Shares Dipped

Although we don't believe in timing the market or panicking over market movements, we do like to ...



Stock Performance

View Interactive TEAR Charts
Sponsored by

Key Data Points

Primary metrics and data points about TearLab.
Current Price: $0.47
Prev Close: $0.52
Open: $0.52
Bid: $0.46
Ask: $0.58
Day's Range: $0.43 - $0.54
52wk Range: $0.43 - $1.75
Volume: 772,406
Avg Vol 98,118
Market Cap: $16M
P/E (ttm): -0.61
EPS (ttm): ($0.85)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about TearLab.
CAPS Rating 1 out of 5
 
22 Outperform
11 Underperform
CAPS All Stars
 
2 Outperform
8 Underperform

How do you think TearLab will perform against the market?



You pick for TearLab is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Elias Vamvakas, CEO

100% Approve

Based on 4 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for TearLab.

An ophthalmic therapeutic company in the business of commercializing innovative treatments for age-related eye diseases, including age-related macular degeneration, or AMD, and glaucoma.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Healthcare IT